Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 3
Abstract
The online version of this article (doi:10.1208/s12248-016-9889-y) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Christopher R. Jones, Oliver J. D. Hatley, Anna-Lena Ungell, Constanze Hilgendorf, Sheila Annie Peters, Amin Rostami-Hodjegan
Keywords
Related Articles
- EP ID EP680868
- DOI 10.1208/s12248-016-9889-y
- Views 51
- Downloads 0
Pulmonary Toxicity of Polysorbate-80-coated Inhalable Nanoparticles; In vitro and In vivo Evaluation
Using inhalable nanoparticles (NPs) to treat pulmonary diseases is an emerging field (1). Lungs as part of the mononuclear phagocyte system (MPS) are extensively rich with alveolar macrophages (2). These alveolar macroph...
Transporter and ion channel gene expression after caco-2 cell differentiation using 2 different microarray technologies
mRNA expression profiles had previously been measured in Caco-2 cells (human colonic carcinoma cells) using either custom-designed spotted oligonucleotide arrays or Affymetrix GeneChip oligonucleotide arrays. The Caco-2...
A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development
We designed a three-step statistical approach to transfer bioanalytical assays (ELISA and Biacore) which evaluates the (1) average equivalence between the two labs (2) concordance in individual sample results between the...
Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop
There have been some successes in qualifying biomarkers and applying them to drug development and clinical treatment of various diseases. A recent success is illustrated by a collaborative effort among the US Food and Dr...
Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications
It is widely believed that acceptable bioequivalence studies of drugs with high within-subject pharmacokinetic variability must enroll higher numbers of subjects than studies of drugs with lower variability. We studied t...